Media OutReach
Johnson & Johnson and Asia Pacific Patient Advocacy Group Leaders Unite to Strengthen Shared Decision-Making in Lung Cancer Care
J&J deepens its commitment to patient empowerment in Asia Pacific by launching J&J withMe, a new patient portal offering tailored patient resources, and co-driving market-specific initiatives with patient advocacy groups
SINGAPORE – Media OutReach Newswire – 11 December 2025 – Johnson & Johnson announced the next phase of The 3rd Opinion campaign across Asia Pacific, focused on championing shared decision-making between lung cancer patients and healthcare professionals through events and stakeholder engagements at ESMO Asia 2025 in Singapore.
At a Patient Reception on 6th December 2025, 20 leaders from 17 patient advocacy groups from across Asia Pacific, Europe and the United States shared their support for the need to strengthen shared decision-making. On December 7, 2025, the ESMO Asia 2025 Symposium, ‘Advancing EGFRm NSCLC Treatment Through Shared Decision-Making’ highlighted the role of healthcare professionals not only in making sense of the data but also in helping patients and their families navigate complex decision-making.
“High prevalence in Asia of certain NSCLC mutations makes the choice of first-line therapy absolutely critical. Treatment decisions must balance clinical objectives with patient values — weighing disease biology, survival prospects, durable disease control and the tradeoffs of side effects. That’s why shared decision-making is essential: clinicians should present all appropriate treatment options, so the final choice is collaborative and aligned with each patient’s goals,” said Professor Zhu Zhengfei, Director of the Radiation Oncology Department, Fudan University Shanghai Cancer Center.
“When lung cancer patients are empowered to speak up and understand their options, they are more likely to continue the treatment and their dignity is preserved. Initiatives like ‘The 3rd Opinion’ are vital for fostering truly patient-centered partnerships between people living with cancer and their healthcare teams,” noted Ms. Liu Yiting, Marketing & Branding Director, China MeetHealth Mi-Jian Patient Community.
“The shared commitment validates what many people living with lung cancer have long expressed: shared decision making is essential. From our experience supporting patients, meaningful conversations with clinicians help acknowledge patients’ experiences, address their concerns, and preserving their hopes,” added Mr. Jung-Il Cho, Chairman of Korea Lung Cancer Patients Association.
Our commitment comes off the back of a recent patient survey revealing that 90% of Japanese lung cancer patients want to play an active role in their treatment decisions. The survey also found that shared decision-making, where physicians and patients jointly compare treatment options and decide together, is the strongest driver of treatment satisfaction.1
Patient survey finds that those engaged in shared decision-making were 11 times more likely to report higher satisfaction with their treatments, with 90% of lung cancer patients in Japan wanting to play an active role in their treatment decisions. This finding underscores the importance of shared decision-making and patient-centered care.1
To bridge the gap between patients’ desire to engage in shared decision making and their lack of practical support, J&J has launched “J&J withMe”, an online hub that equips lung cancer patients and caregivers with tailored toolkits and conversation guides to prepare for consultations and make informed, personalized treatment decisions.
Anthony Elgamal, Vice President of Oncology, Johnson & Johnson Innovative Medicine Asia Pacific said, “The 3rd Opinion truly puts patients at the center of care. As part of our deep commitment to address patients’ unmet needs, we will continue partnering with patient advocacy groups and healthcare professionals to help patients to find their voice and the moment when medical advice meets what truly matters to patients.”
In recognition of diverse cultural and clinical norms across Asia Pacific, J&J has also rolled out tailored market activations in collaboration with local patient advocacy groups:
- Provision of patient resources such as the “Lung Cancer Book of Answers” in China, ‘Value of Time’ video for patients in Japan, and educational assets in India and Australia/New Zealand;
- Digital and social media engagement featuring patients and creators discussing the importance of shared decision-making across Singapore, Malaysia, Philippines, Thailand, and Vietnam;
- Event engagement via the establishment of a patient advisory board in India;
- Corporate Social Responsibility program with a lung cancer patient group in Korea, bringing employees and patients together to better understand the disease burden of patients and strengthen emotional support for the patient community.
###
About the 3rd Opinion
“The 3rd Opinion”, the patient’s own opinion, is a new term that sparks a social movement in the lung cancer treatment journey – designed to elevate the patient voice and empower individuals to take an active role in shaping their treatment plan. By prioritizing shared decision-making between patients and healthcare professionals, this collaborative approach ensures that treatment choices are aligned to each patient’s goals, preferences and circumstances. This results in more informed decisions, greater patient satisfaction, and the best possible outcomes.
About Non-Small Cell Lung Cancer
Worldwide, lung cancer is one of the most common cancers, with NSCLC making up 80 to 85 percent of all lung cancer cases.[1], [2] The main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.[3] Among the most common driver mutations in NSCLC are alterations in EGFR, which is a receptor tyrosine kinase controlling cell growth and division.[4] EGFR mutations are present in 10 to 15 percent of Western patients with NSCLC with adenocarcinoma histology and occur in 40 to 50 percent of Asian patients.[5], [6],[7],[8],[9],[10] EGFR ex19del or EGFR L858R mutations are the most common EGFR mutations.[11] The five-year survival rate for all people with advanced NSCLC and EGFR mutations treated with EGFR tyrosine kinase inhibitors (TKIs) is less than 20 percent.[12],[13] EGFR exon 20 insertion mutations are the third most prevalent activating EGFR mutation.[14] Patients with EGFR exon 20 insertion mutations have a real-world five-year overall survival (OS) of eight percent in the frontline setting, which is worse than patients with EGFR ex19del or L858R mutations, who have a real-world five-year OS of 19 percent.[15]By comparison, other common cancers, such as breast and prostate cancer have a 5-year real world OS of 90% and 97% respectively[16].
[2] The World Health Organization. Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed March 2025.
Hashtag: #Johnson&Johnson
The issuer is solely responsible for the content of this announcement.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.
Learn more at 
https://www.jnj.com/ or at www.innovativemedicine.jnj.com. Follow us at @JNJInnovMed.
Johnson & Johnson Innovative Medicine Asia Pacific, a division of Johnson & Johnson International (Singapore) Pte. Ltd is a Johnson & Johnson company.
© Johnson & Johnson International (Singapore) Pte. Ltd. [2025] All rights reserved.
Media OutReach
From PolyU Research to Geneva Global Debut: GOOD Vision oka³y! ™ Redefines Precision in Freeform Orthokeratology
Beyond Traditional Toric Lenses: The Future of Freeform Orthokeratology
With myopia expected to affect 50% of the world’s population by 2050, demand for effective management is high. While Ortho-K is a highly effective strategy, traditional symmetric and spherical/ toric designs often underestimate corneal shape complexity, causing lens decentration and poor visual outcomes.
The oka³y!™ freeform technology, incorporating the company’s proprietary FAST-360 and CORe Technology, surpasses traditional lens design. AI-based FAST-360 reconstructs missing corneal data for faster scans, while CORe ensures precise alignment with the visual axis, leading to 3.1 times greater stability.
Precision Myopia Correction and Control for High Astigmatism and Asymmetric Corneas
For optometrists and clinic owners, oka³y!™’s key benefit is improving workflow by automating complex mathematics, cutting chair time by 64%. This boosts myopia management capacity without extra staff or lengthy training. “As a registered optometrist in Hong Kong and a researcher in one of the world’s leading optometric institutes, I witnessed a growing gap between the number of patients seeking Ortho-K and the limited range of conventional products available to treat them,” says Dr. Kin Ho Chan, Ken, the lead inventor of oka³y!™. “By focusing on the ‘3A’: AI-guided, Astigmatism, and Asymmetry, and working alongside The Hong Kong Polytechnic University (Poly U), we have developed a design that not only delivers superior vision but also enhances safety by reducing corneal staining. We are turning a frustrating, manual trial-and-error process into a predictable one-click adjustment.”
From Niche Specialty to Global Enterprise: Scaling the Future of Eye Care
As myopia rates reach epidemic levels, GOOD Vision partners with PolyU, harnessing its research strengths and support from its startup ecosystem PolyVentures, to redefine primary eye care by transforming a niche specialty into a scalable global enterprise. By replacing manual OK lens design with oka³y!™, the company has created a technology bridging clinical complexity and scalability. This transition enables practitioners to manage myopia, high astigmatism, and asymmetrical cases precisely, removing barriers to modern refractive error management.
“By embedding and automating the complex mathematics of lens design, we provide clinicians with the tools to treat ‘difficult’ patients who were previously considered unsuitable for Ortho-K,” added Professor Chea-su Kee, Founder of GOOD Vision. “This is about elevating the global standard of care and ensuring that precision myopia management is accessible to the next generation on a global scale.”
Experience the Future of Myopia Control
GOOD Vision invites investors, distributors, and practitioners to a live demonstration of the oka³y!™ at the International Exhibition of Inventions Geneva:
- Location: PolyU Delegation Booth, Hall 2, Palexpo, CP 112, Route François-Peyrot 30, 1218 Le Grand-Saconnex, Geneva, Switzerland
- Dates: 11–15 March 2026
Hashtag: #GOODVision
The issuer is solely responsible for the content of this announcement.
About GOOD Vision Technologies Co., Limited
GOOD Vision, a Hong Kong-based startup nurtured by PolyU, is dedicated to advancing the field of corneal reshaping technologies. With a focus on innovation, efficiency, and affordability, the company develops innovative solutions to empower eye practitioners and enhance the quality of eye care worldwide.
For additional details about GOOD Vision and their innovative offerings, please visit https://www.linkedin.com/company/goodvisiontech
Central Landmark Set for Revitalization with International Expertise
HONG KONG SAR – Media OutReach Newswire – 9 March 2026 – In a vote of confidence in Hong Kong’s vibrant and enduring business environment, Nexxus Building, a landmark Grade‑A commercial property in Central’s prestigious CBD, has been acquired by a leading figure in the technology sector. Trivium Asset Management (“Trivium”), an Asian real estate investment and asset management firm, has been appointed as Nexxus Building’s Asset Manager (“AMC” or Asset Management Company), taking charge of the asset’s comprehensive management and operations.
Under new ownership, Nexxus Building is set to undergo a forward‑looking transformation integrating next‑generation technologies with world‑class professional management. The revitalization aims to redefine the building’s market positioning, enhance its tenant experience, and reinforce its status as an iconic and premier Grade‑A property in the heart of Hong Kong’s CBD.
Leveraging Trivium’s extensive expertise, the enhancement programme will incorporate smart‑building management systems and sustainability‑driven upgrades designed to meet the evolving needs of global tenants. The reimagined Nexxus Building aims to attract financial institutions, fintech platforms, and technology enterprises, reaffirming Central’s position as Asia’s dynamic financial and innovation hub.
Mr. Wilfred Ma, Managing Partner of Trivium Asset Management, said, “Trivium is honored to be entrusted with the role of Asset Manager (“AMC” or Asset Management Company) for Nexxus Building, one of Hong Kong’s most iconic commercial landmarks. Drawing on our track record in real estate investment and operations across Hong Kong and Japan, we are committed to implementing forward‑thinking strategies that enhance tenant value, optimize building performance, and unlock Nexxus Building’s full potential as a commercial anchor in the city’s core.”
Originally built in 1962 as the former headquarters of Hang Seng Bank, Nexxus Building has been a witness to Hong Kong’s rise as a global financial centre. Following a major renovation in 2008 and the addition of a direct footbridge to IFC and the Airport Express in 2020, the building continues to host multinational corporations, leading financial institutions and professional services firms, and premium retail tenants – including the iconic Hong Kong Bankers Club – reinforcing its status as one of Central’s most distinguished Grade‑A office towers.
Hashtag: #TriviumAssetManagement
The issuer is solely responsible for the content of this announcement.
About Trivium Asset Management
Founded in 2022, Trivium Asset Management is a Hong Kong‑based real estate investment and asset management firm overseeing assets valued at over US$900 million across Asia. Trivium serves institutional investors, financial institutions, and family offices through integrated investment and asset management, value‑creation strategies, and technology integration. The firm’s mission is to maximize long‑term value and promote sustainable growth for clients and communities alike.
Media OutReach
HOFA Announces the Second Edition of the Digital Art Awards, in Collaboration with Exhibition Partner PhillipsX in Hong Kong, proudly backed by Lightyear
The awards ceremony will take place on 24 March 2026, featuring the four key categories of Still Image, Moving Image, Innovation and Experiential and followed by a private sale exhibition hosted by Phillips in Hong Kong, from 25–28 March 2026.
As a highlight of Hong Kong’s spring art calendar, the awards celebrate the growing cultural significance of digital art and spotlights the visionary artists redefining visual culture through cutting-edge technologies.
Thirty two international finalists will be selected for their work pushing the boundaries of digital creativity. Each of the four category winners will receive a $10,000 USDC commission towards a new artwork.
The thirty two finalists include several prominent figures in digital and generative art, such as Erick Calderon (Snowfro) Founder of Art Blocks, Botto, Sarah Meyohas, William Mapan, Sasha Stiles and Mario Klingemann – underscoring the calibre of talent the awards are already attracting with over two hundred applications across more than fifty countries.
Refik Anadol is nominated for the Honorary Career Award for Sense of Healing, an AI Data Sculpture that emerges from Refik Anadol Studio’s long-term research into creating meditative art based on neurological data.
Finalists and winners will be selected by a panel of leading experts in art, hospitality and technology, including Irini Mirena Papadimitriou, Exhibitions Director at Diriyah Art Futures, Thomas Heyne, Co-Founder and CEO at Scorpios, Dorothy di Stefano, Art Curator and Creative Strategist at Molten Immersive Art, Danielle So, Hong Kong Head of Auction, Modern & Contemporary Art, Phillips, Sebastien Borget, Co-Founder & Global of The Sandbox, SANDchain, President of Blockchain Game Alliance and Co-Founder of Artverse, Jean-Michel Pailhon, Co-Founder and Chief Investment Officer at Grailcapital, Simonida Pavicevic, Co-Founder and Curator at HOFA, Justin Gilanyi, Founder of WhereArt.Works and Curator at SILK, and Matt Zhang, Founder and Managing Partner at Hivemind Capital.
The Digital Art Awards are proudly backed by Lightyear, a subsidiary of Hivemind Digital Group. A full-stack digital culture partner, Lightyear provides infrastructure, liquidity and market expertise, and hands-on delivery for digital ownership and engagement across physical and digital experiences. Lightyear is committed to championing artists and organizations pushing the boundaries of digital culture.
Hashtag: #HOFA #PhillipsX
The issuer is solely responsible for the content of this announcement.
-
Feature/OPED6 years agoDavos was Different this year
-
Travel/Tourism10 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz3 years agoEstranged Lover Releases Videos of Empress Njamah Bathing
-
Banking8 years agoSort Codes of GTBank Branches in Nigeria
-
Economy3 years agoSubsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking3 years agoSort Codes of UBA Branches in Nigeria
-
Banking3 years agoFirst Bank Announces Planned Downtime
-
Sports3 years agoHighest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn